IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
AssigneeGenentech, Inc.
InventorsJustin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
Life of this patent
Estimating the term…
Abstract
The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
Claims48
1-157. (canceled)
A method of accelerating or improving wound healing in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier,
- wherein the IL-22 Fc fusion protein comprises an IL-22 polypeptide linked to an IgG Fc region by a linker, wherein the Fc region comprises a hinge region, an IgG CH2 domain and an IgG CH3 domain, wherein the IL-22 Fc fusion protein comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:8, and wherein the Fc region is not glycosylated at amino acid residue N297.
A method of accelerating or improving wound healing in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising an IL-22 polypeptide, or an IL-22 Fc fusion protein comprising an IL-22 polypeptide linked to an IgG Fc region by a linker, wherein the Fc region comprises a hinge region, an IgG CH2 domain and an IgG CH3 domain, wherein the IL-22 Fc fusion protein comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:8, and wherein the Fc region is not glycosylated at amino acid residue N297.
Dependencies are inferred from the claim text.